Can Fite Biopharma (NYSEAMERICAN:CANF) continued to trade in a narrow range on Wednesday and ended slightly lower.
Market Action
On Wednesday, CANF stock fell 0.94% to $2.11. The stock had traded 313K shares for the session, well below its average volume of 3.31 million shares.
Can-Fite to Present at BIO Digital International Convention & Conduct One-on-One Meetings with Potential Partners on June 10-18, 2021
- announced the Company’s Vice President of Business Development Dr. Sari Fishman will present at the BIO Digital International Convention and participate in one-on-one meetings with potential licensing and distribution partners on June 10-11 & 14-18, 2021. Over 3,800 delegates from 2,300 companies are registered for BIO One-on-One Partnering.
Can-Fite currently has out-licensing agreements for its Namodenoson and Piclidenoson drug candidates in several territories and has received approximately $20 million in upfront and milestone payments to date with additional potential milestone payments of up to approximately $130 million, plus double-digit royalties on net sales following regulatory approval. “We look forward to productive meetings with potential partners in untapped territories for our drug candidates as we approach several milestones before year-end including announcing topline data from our Phase III psoriasis trial and Phase II COVID-19 study, as well as commencing a pivotal Phase III in liver cancer and a Phase IIb in NASH,” stated Can-Fite CEO Dr. Pnina Fishman.
){kind=link}